Generic Name: Carvedilol
Product Name: Dilatrend
Indication of Dilatrend
Dilatrend is used in the treatment of heart failure. It does this by reducing the pressure the heart has to pump against (blood pressure) and controlling the heart rate. Dilatrend is often used in conjunction with other medications.
Action of Dilatrend
Dilatrend is a beta-blocking agent used in heart failure. Its actions include:
Dose advice of Dilatrend
Your doctor will tell you how many DILATREND tablets to take each day.
Schedule of Dilatrend
Common side effects of Dilatrend
There are some common side effects associated with Dilatrend. It is important to tell the doctor if they occur and are worrying you. These include:
Uncommon side effects of Dilatrend
There are several rare but important side effects that can be associated with Dilatrend. If these occur, you should tell your doctor immediately or present to the nearest Accident and Emergency hospital department, as urgent medical attention may be required. These include:
 Bicor (R) Australian Approved Product Information Dilatrend (R) Australian Approved Product Information Toprol-XL TM Approved Product Information Fowler MB, Vera-Llonch M, et al. Influence of Carvedilol on Hospitalisations in Heart Failure Incidence, Resource Uitilisation and Costs. Journal of the American College of Cardiology 2001, 37(6): 1692-1699.  Keating GM, Jarvis B. Carvedilol. A review of its use in chronic Heart Failure. Adis Drug Evaluation; Drugs 2003, 63(16): 1-43. Parker M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patints with chronic heart failure. N Engl J Med 1996, 334; 1349-1355. Parker M, Coat AJS, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344 (22); 1651-1658. Remme WJ, Riegger G, Hildebrandt P et al. Clinical Trials, The Benefits of Early Combination Treatment of Carvedilol and an ACE-Inhibitor in Mild Heart Failure and Left Ventricular Systolic Dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN). Cardiovascular Drugs and Therapy 2004; 18: 57-66. Packer M, Fowler M, et al. Results of the Carvedilol Prospective Randomised Cumulative Survival (COPERNICUS) Study. Circulation 2002; 106: 2194-2199.
For further information talk to your doctor.